Core Viewpoint - China Resources Double Crane (华润双鹤) has received approval for two significant pharmaceutical products, indicating potential growth in its product portfolio and market presence [1] Group 1: Product Approvals - The wholly-owned subsidiary, China Resources Zizhu Pharmaceutical Co., Ltd., received a drug supplement approval notice for Olopatadine Hydrochloride Eye Drops from the National Medical Products Administration (NMPA) [1] - The approval notice numbers are 2025B01154 and 2025B01155, highlighting the regulatory progress for the product [1] - The eye drops are intended for treating the signs and symptoms of allergic conjunctivitis, developed in collaboration with Nanjing Hengdao Pharmaceutical Technology Co., Ltd. [1] Group 2: Raw Material Approval - The controlling subsidiary, Zhejiang Xinsai Pharmaceutical Co., Ltd., received a marketing approval notice for Fenofibrate Choline Raw Material from the NMPA [1] - The approval notice number is 2025YS00306, indicating successful regulatory compliance for the raw material [1] - Fenofibrate is used to lower triglyceride levels in patients with severe hypertriglyceridemia and for treating primary hypercholesterolemia or mixed dyslipidemia [1]